Skip to main content

Table 2 Research priorities in COVID-19-related acute respiratory failure

From: Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method

Pathophysiology

Exploration of “personalised” respiratory interventions based on phenotypes (using clinical, physiological, biological or radiological criteria)

Awake self-proning

Optimal technique (such as complete prone or side to side), timing and duration

Impact on escalation of respiratory support, tracheal intubation and mortality

Effect of combination with HFNO or NIV on outcome measures

HFNO

Risk of aerosolisation, optimal setting, monitoring and prediction of failure

Comparison with NIV/CPAP and weaning strategies

Use in moderate-to-severe hypoxemia (PaO2/FiO2 less than 200 mm Hg)

Impact on outcomes (ICU/hospital length of stay and mortality)

NIV (including CPAP)

Risk of aerosolisation, monitoring, helmet versus other interfaces

Multimodal strategies with HFNO

Impact on escalation of respiratory support, outcomes (ICU/hospital length of stay and mortality)

Impact of NIV in subset of patients with mixed respiratory failure, cardiogenic pulmonary oedema and COVID-19-related ARDS

Corticosteroids

Effect of timing of initiation, different types, dose, optimal duration, tapering schedule

Impact of laboratory biomarkers on timing, dose and duration of corticosteroid

Interaction of corticosteroids with other COVID-19 therapeutics such as Remdesivir, Baricitinib, etc

Invasive mechanical ventilation

Initiation of invasive mechanical ventilation: Optimal timing, triggers and technique with respect to patient and HCW safety

Impact of non-conventional ventilation strategies based on respiratory mechanics on outcomes (ICU/hospital length of stay and mortality)

Sedation and NMBA: Optimal sedation strategy and monitoring techniques. Timing, duration, technique (continuous versus bolus) and monitoring of NMBA

PEEP: Strategy for personalisation and method of selection

Fluid management: Restrictive versus liberal. Impact on ARDS phenotypes

Assessing fluid responsiveness

Weaning and liberation: Optimal timing and strategy. Impact of HFNO or NIV post-extubation. Predictive measures for failure

ECMO: Optimal timing and patient selection. Resource planning in the constraints of a pandemic

Tracheostomy

Optimal timing, strategy for HCWs safety and post-procedure care. Direct effect of SARS-CoV-2 virus on larynx and trachea

Infection control

Strategy for HCWs safety during aerosol generating procedures in resource limited settings

Role of different types of PPE and strategies to optimize their use

De-escalation of isolation precautions: time and/or testing based

Impact of different interventional strategies on the reduction in aerosolisation

Efficacy and safety of tele-ICU or remote monitoring to limit exposure

  1. HFNO: high-flow nasal oxygen; NIV: non-invasive ventilation; CPAP: continuous positive airway pressure; ICU: intensive care unit; COVID-19: coronavirus disease 2019; ARDS: acute respiratory distress syndrome; HCW: healthcare worker; NMBA: neuromuscular blocking agent; PEEP: positive end-expiratory pressure; ECMO: extracorporeal membrane oxygenation; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; PPE: personal protective equipment